Cardiology

Re-analysis of diabetes drug finds no higher heart attack risk

A re-analysis of the data from a pivotal study of rosiglitazone found no increased risk of cardiovascular events associated with the controversial diabetes drug, according to researchers at the Duke Clinical Research Institute ...

page 13 from 18